Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.

Hepatology (Baltimore, Md.) - 1 Oct 2004

Di Marco Vito, Marzano Alfredo, Lampertico Pietro, Andreone Pietro, Santantonio Teresa, Almasio Piero Luigi, Rizzetto Mario, Craxì Antonio

Abstract excerpt

The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis is unclear. In a retrospective multicenter study, we have analyzed the virological events observed during lamivudine therapy in patients with HBeAg-negative chronic hepatitis and evaluated the correlation between virological response and clinical outcomes. Among 656 patients (mean age 49.1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Liver Transplantation

Share to Multivariate Analysis

Share to Reverse Transcriptase Inhibitors

Share to Survival Rate

Source

Identifiers

PMID: 15382125
DOI: 10.1002/hep.20381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.PMID 15382125Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.Semantic proximity Read ↗

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.Semantic proximity Read ↗

Determinants for sustained HBeAg response to lamivudine therapy.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.Semantic proximity Read ↗

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.Semantic proximity Read ↗

High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.Semantic proximity Read ↗

Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.Semantic proximity Read ↗

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.Semantic proximity Read ↗

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.